AR134792A1 - Inhibidor de tyk2 y uso del mismo - Google Patents
Inhibidor de tyk2 y uso del mismoInfo
- Publication number
- AR134792A1 AR134792A1 ARP240103585A ARP240103585A AR134792A1 AR 134792 A1 AR134792 A1 AR 134792A1 AR P240103585 A ARP240103585 A AR P240103585A AR P240103585 A ARP240103585 A AR P240103585A AR 134792 A1 AR134792 A1 AR 134792A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- tyk2
- tyk2 inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a un compuesto de siguiente Fórmula Química (1), un isómero óptico del mismo, un estereoisómero del mismo, un solvato del mismo, un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo, y una composición farmacéutica que incluye el mismo, y el compuesto o la sal farmacéuticamente aceptable del mismo de acuerdo con la presente divulgación puede ser utilizado eficazmente para la prevención, mejora o tratamiento de enfermedades relacionadas con TYK2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20230187651 | 2023-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR134792A1 true AR134792A1 (es) | 2026-04-01 |
Family
ID=96137567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240103585A AR134792A1 (es) | 2023-12-20 | 2024-12-20 | Inhibidor de tyk2 y uso del mismo |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR20250096635A (es) |
| AR (1) | AR134792A1 (es) |
| WO (1) | WO2025135870A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007106349A2 (en) * | 2006-03-10 | 2007-09-20 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues |
| KR20150028999A (ko) * | 2012-06-27 | 2015-03-17 | 에프. 호프만-라 로슈 아게 | 5-아자인다졸 화합물 및 이의 사용 방법 |
| WO2022204235A1 (en) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
| WO2022242697A1 (zh) * | 2021-05-19 | 2022-11-24 | 南京药石科技股份有限公司 | Tyk2选择性抑制剂及其用途 |
| WO2023220046A1 (en) * | 2022-05-10 | 2023-11-16 | Biogen Ma Inc. | Tyk2 inhibitors |
-
2024
- 2024-12-20 AR ARP240103585A patent/AR134792A1/es unknown
- 2024-12-20 KR KR1020240192757A patent/KR20250096635A/ko active Pending
- 2024-12-20 WO PCT/KR2024/020810 patent/WO2025135870A1/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250096635A (ko) | 2025-06-27 |
| WO2025135870A1 (ko) | 2025-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000196A1 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| MX2024002538A (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t. | |
| AR133968A1 (es) | Nuevo compuesto derivado de ftalazina como inhibidor de sos1 y uso del mismo | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| DOP2024000146A (es) | Inhibidores de parp7 | |
| AR127501A1 (es) | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos | |
| AR131639A1 (es) | Inhibidores de kif18a y usos de los mismos | |
| CL2025000529A1 (es) | Compuestos derivados de dioxoisoquinolinona, inhibidores de ezh1 y/o ezh2; uso para tratar cáncer. | |
| MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| DOP2025000167A (es) | Inhibidores de prmt5mta | |
| AR128932A1 (es) | Inhibidores de bcl-xl | |
| AR132166A1 (es) | Inhibidores de inflamasoma nlrp3 y usos de los mismos | |
| CL2025001119A1 (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| CL2024000657A1 (es) | Azálidos inmunomoduladores | |
| CO2025018006A2 (es) | Formas sólidas de un inhibidor macrocíclico de farnesiltransferasa y formulaciones de estos, y métodos de preparación y uso del compuesto macrocíclico y sus formas sólidas | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica | |
| MX2025008207A (es) | Estereoisomero y derivado deuterado de compuesto de pirazoloquinazolina y uso | |
| AR133788A1 (es) | Inhibidores de parp7 | |
| MX2022005415A (es) | Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo. | |
| AR133286A1 (es) | Inhibidores ra2s heterocíclicos de igf-1r para el tratamiento de enfermedades | |
| AR131842A1 (es) | Métodos para tratar gliomas |